Senogles S E, Nelsestuen G L
J Biol Chem. 1983 Oct 25;258(20):12327-33.
von Willebrand factor (VWF) functions in platelet aggregation, a form of cellular interaction. In vitro analysis of platelet aggregation, as measured by the platelet aggregometer, requires addition of a promoter such as the glycopeptide antibiotic ristocetin. Native multimeric VWF (Mr = 1-20 X 10(6)) can be reduced with sulfhydryl reagents to a monomeric state (Mr = 2 X 10(5)). In this study, the binding of bovine VWF and ristocetin to bovine platelets was investigated using fluorescence anisotropy of derivatized monomer protein and ristocetin and also by radioisotope methods using 125I-labeled monomer and native protein. Ristocetin bound to bovine platelets but not to VWF. VWF binding to formaldehyde-fixed platelets was dependent on the presence of a promoter such as ristocetin. The monomer and multimer VWF bound equally well in the presence of low ristocetin concentrations. Under these conditions, plots of VWF binding versus platelet concentration were sigmoidal, indicating positive cooperativity with respect to platelets. At higher (100 micrograms/ml) ristocetin concentrations, the binding curve was no longer sigmoidal. Ristocetin promoted the formation of small platelet aggregates, an effect that was amplified by the presence of VWF. In fact, all conditions which resulted in monomer or multimer VWF binding to platelets also caused formation of platelet aggregates observed by light microscopy. These combined results were consistent with VWF binding only to the interface between proximal platelets. High affinity binding could be provided by the presence of two cell surfaces and the resulting multiple binding interactions. Polycations, such as poly(L-lysine) and Polybrene, also promoted the formation of platelet aggregates and facilitated the binding of VWF to platelets. Physiological platelet activators such as thrombin, ADP, and collagen also facilitated VWF binding to native platelets and caused platelet aggregation. It appears possible that any process which causes the surface membranes of platelets to become spatially close will allow expression of VWF activity.
血管性血友病因子(VWF)在血小板聚集中发挥作用,血小板聚集是一种细胞间相互作用形式。通过血小板聚集仪测量的血小板聚集的体外分析需要添加一种启动剂,如糖肽抗生素瑞斯托霉素。天然多聚体VWF(Mr = 1 - 20×10⁶)可用巯基试剂还原为单体状态(Mr = 2×10⁵)。在本研究中,使用衍生化单体蛋白和瑞斯托霉素的荧光偏振以及使用¹²⁵I标记的单体和天然蛋白的放射性同位素方法,研究了牛VWF和瑞斯托霉素与牛血小板的结合。瑞斯托霉素与牛血小板结合,但不与VWF结合。VWF与甲醛固定血小板的结合取决于启动剂如瑞斯托霉素的存在。在低瑞斯托霉素浓度下,单体和多聚体VWF的结合效果相同。在这些条件下,VWF结合与血小板浓度的关系图呈S形,表明对血小板具有正协同性。在较高(100微克/毫升)瑞斯托霉素浓度下,结合曲线不再呈S形。瑞斯托霉素促进小血小板聚集体的形成,VWF的存在会放大这种效应。事实上,所有导致单体或多聚体VWF与血小板结合的条件也会导致通过光学显微镜观察到的血小板聚集体的形成。这些综合结果与VWF仅结合到近端血小板之间的界面一致。两个细胞表面的存在以及由此产生的多重结合相互作用可以提供高亲和力结合。聚阳离子,如聚(L - 赖氨酸)和聚凝胺,也促进血小板聚集体的形成并促进VWF与血小板的结合。生理血小板激活剂如凝血酶、ADP和胶原蛋白也促进VWF与天然血小板的结合并导致血小板聚集。看来任何导致血小板表面膜在空间上靠近的过程都将允许VWF活性的表达。